Brief: Merus Announces First Patient Dosed In Phase 2 Trial Of Petosemtamab In 3L+ Mcrc
16/12/2024 21:14
Dec 16 (Reuters) - Merus NV 2GH.F :
* MERUS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 TRIAL OF
PETOSEMTAMAB IN 3L+ MCRC
Source text: ID:nGNX3NjmkV
Further company coverage: 2GH.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab